Please assess the completion status of the following clinical trial:

Trial Title: Once Weekly GLP-1 in Persons With Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, age 18 to 69;~2. Chronic (e.g., duration of injury greater than 3 years) stable SCI (regardless of level of neurological injury);~3. ASIA A-D (non-ambulatory defined as not able to weight bear for more than 20% of the day);~4. Obese Percent Body Fat defined as \> 25% for men and \> 35% for women (as determined by screening DXA scan);~5. Insulin Resistant as determined at screening: (FPI, ≥15 µU/ml); -OR-~6. Pre-diabetic, as determined by any one of the following:~   1. HbA1C ≥ 5.7% and \< 6.4%; or~  2. Impaired glucose tolerance by FSG ≥100 mg/dl and \< 125 mg/dl and/or the 2 hour serum glucose concentration (after an OGTT) ≥ 140 mg/dl and \< 200 mg/dl~Exclusion Criteria:~1. Personal history of or family history of medullary thyroid carcinoma;~2. History of multiple endocrine neoplasia syndrome type 2;~3. History of pancreatitis;~4. Existing diagnosis of diabetes mellitus, or the results from screening OGTT that identify diabetes mellitus (previously undiagnosed); laboratory thresholds for exclusion will be as follows: HbA1C ≥6.5%, fasting plasma glucose \>126 mg/dl, or 2 hour value \>200 mg/dl;~5. Receiving treatment for impaired glucose metabolism (i.e., insulin, secretagogues, or other agents to modify peripheral insulin sensitivity or serum glucose concentration);~6. Reduced kidney function (by glomerular filtration rate (GFR \<60 ml/min) or liver function tests (any single LFT ≥ 2.5 times above the upper limit of normal) as determined by test results at screening and any time point of the study;~7. Elevated calcitonin level (as determined at screening to rule out thyroid cancer);~8. Pregnancy or women who may become pregnant during the course of the study, or those who are nursing;~9. Medically unstable;~10. Acute illness or infection;~11. Diminished mental capacity; and~12. Inability or unwillingness of subject to provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Semaglutide 1MG Injection [Ozempic] (Type: EXPERIMENTAL): 20 subjects will be randomized to receive once weekly injection of Semaglutide (Ozempic1mg) for 26 weeks.
- No Intervention (Type: OTHER): 10 subjects will be randomized to receive no intervention for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).